NeoRecormon

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

epoetin beta

Available from:

Roche Registration GmbH

ATC code:

B03XA01

INN (International Name):

epoetin beta

Therapeutic group:

Antianemijski pripravci

Therapeutic area:

Kidney Failure, Chronic; Anemia; Cancer; Blood Transfusion, Autologous

Therapeutic indications:

Liječenje simptomatske anemije, povezane s kroničnom bubrežnom insuficijencijom (CRF) i педиатрические pacijenti odrasla osoba;liječenje simptomatske anemije kod odraslih pacijenata s миелоидными maligna новообразованиями primaju kemoterapiju;povećanje prinosa аутокрови kod bolesnika u pre-дарственной programa. Njegova upotreba u ovoj brojila moraju biti уравновешены je obaviješten o povećanju rizika тромбоэмболических komplikacija . Liječenje bi trebalo biti dano samo za bolesnike s umjerenom anemičan (PERSOPN 10 - 13 g/dl [6. 21 - 8. 07 mmol/l], bez nedostatka željeza), ako je postupak spremanja krvi nema ili je nedovoljna za planirani veliki planska operacija zahtijeva velike količine krvi (4 i više jedinica krvi za žene ili 5 ili više jedinica za muškarce).

Product summary:

Revision: 33

Authorization status:

odobren

Authorization date:

1997-07-16

Patient Information leaflet

                                48
B. UPUTA O LIJEKU
49
UPUTA O LIJEKU: INFORMACIJE ZA KORISNIKA
NEORECORMON 500 IU
NEORECORMON 2000 IU
NEORECORMON 3000 IU
NEORECORMON 4000 IU
NEORECORMON 5000 IU
NEORECORMON 6000 IU
NEORECORMON 10 000 IU
NEORECORMON 20 000 IU
NEORECORMON 30 000 IU
OTOPINA ZA INJEKCIJU U NAPUNJENOJ ŠTRCALJKI
epoetin beta
PAŽLJIVO PROČITAJTE CIJELU UPUTU PRIJE NEGO POČNETE PRIMJENJIVATI
OVAJ LIJEK JER SADRŽI VAMA
VAŽNE PODATKE.
●
Sačuvajte ovu uputu. Možda ćete je trebati ponovno pročitati.
●
Ako imate dodatnih pitanja, obratite se liječniku ili ljekarniku.
●
Ovaj je lijek propisan samo Vama. Nemojte ga davati drugima. Može im
naškoditi, čak i ako
su njihovi znakovi bolesti jednaki Vašima.
●
Ako primijetite bilo koju nuspojavu, potrebno je obavijestiti
liječnika ili ljekarnika. To
uključuje i svaku moguću nuspojavu koja nije navedena u ovoj uputi.
Pogledajte dio 4.
ŠTO SE NALAZI U OVOJ UPUTI:
1.
Što je NeoRecormon i za što se koristi
2.
Što morate znati prije nego počnete primjenjivati NeoRecormon
3.
Kako primjenjivati NeoRecormon
4.
Moguće nuspojave
5.
Kako čuvati NeoRecormon
6.
Sadržaj pakiranja i druge informacije
1. ŠTO JE NEORECORMON I ZA ŠTO SE KORISTI
NeoRecormon je bistra, bezbojna otopina za ubrizgavanje pod kožu (
_supkutano_
) ili u venu
(
_intravenski_
). Sadrži hormon
_epoetin beta_
koji stimulira proizvodnju crvenih krvnih stanica. Epoetin
beta se proizvodi uz pomoć specijalizirane genetičke tehnologije i
djeluje identično prirodnom
hormonu eritropoetinu.
Obavijestite svog liječnika ako se ne osjećate bolje ili se
osjećate lošije.
NeoRecormon je namijenjen za:
●
LIJEČENJE SIMPTOMATSKE ANEMIJE UZROKOVANE KRONIČNOM BOLESTI BUBREGA
(bubrežna
anemija) u bolesnika na dijalizi ili u bolesnika koji još nisu na
dijalizi.
●
SPRJEČAVANJE ANEMIJE U NEDONOŠČADI
(mase 750 do 1500 g, rođenih prije 34. tjedna trudnoće).
●
LIJEČENJE ANEMIJE S PRIDRUŽENIM SIMPTOMIMA U ODRASLIH BOLESNIKA S
RAKOM KOJI PRIMAJU
KEMOTERAPIJU.
●
LIJEČENJE BOLESNIKA KOJI DONIRAJU VLASTITU KRV
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOG I.
SAŽETAK OPISA SVOJSTAVA LIJEKA
2
1.
NAZIV LIJEKA
NeoRecormon 500 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 2000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 3000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 4000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 5000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 6000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 10 000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 20 000 IU otopina za injekciju u napunjenoj štrcaljki
NeoRecormon 30 000 IU otopina za injekciju u napunjenoj štrcaljki
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
NeoRecormon 500 IU otopina za injekciju u napunjenoj štrcaljki
Jedna napunjena štrcaljka s 0,3 ml otopine za injekciju sadrži 500
internacionalnih jedinica (IU) što
odgovara 4,15 mikrograma epoetina beta* (rekombinantnog ljudskog
eritropoetina).
Jedan mililitar otopine za injekciju sadrži 1667 IU epoetina beta.
NeoRecormon 2000 IU otopina za injekciju u napunjenoj štrcaljki
Jedna napunjena štrcaljka s 0,3 ml otopine za injekciju sadrži 2000
internacionalnih jedinica (IU) što
odgovara 16,6 mikrograma epoetina beta* (rekombinantnog ljudskog
eritropoetina).
Jedan mililitar otopine za injekciju sadrži 6667 IU epoetina beta.
NeoRecormon 3000 IU otopina za injekciju u napunjenoj štrcaljki
Jedna napunjena štrcaljka s 0,3 ml otopine za injekciju sadrži 3000
internacionalnih jedinica (IU) što
odgovara 24,9 mikrograma epoetina beta* (rekombinantnog ljudskog
eritropoetina).
Jedan mililitar otopine za injekciju sadrži 10 000 IU epoetina beta.
NeoRecormon 4000 IU otopina za injekciju u napunjenoj štrcaljki
Jedna napunjena štrcaljka s 0,3 ml otopine za injekciju sadrži 4000
internacionalnih jedinica (IU) što
odgovara 33,2 mikrograma epoetina beta* (rekombinantnog ljudskog
eritropoetina).
Jedan mililitar otopine za injekciju sadrži 13 333 IU epoetina beta.
NeoRecormon 5000 IU otopina za injekciju u napunjenoj štrcaljki
Jedna napu
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 15-03-2023
Public Assessment Report Public Assessment Report Bulgarian 03-12-2015
Patient Information leaflet Patient Information leaflet Spanish 15-03-2023
Public Assessment Report Public Assessment Report Spanish 03-12-2015
Patient Information leaflet Patient Information leaflet Czech 15-03-2023
Public Assessment Report Public Assessment Report Czech 03-12-2015
Patient Information leaflet Patient Information leaflet Danish 15-03-2023
Public Assessment Report Public Assessment Report Danish 03-12-2015
Patient Information leaflet Patient Information leaflet German 15-03-2023
Public Assessment Report Public Assessment Report German 03-12-2015
Patient Information leaflet Patient Information leaflet Estonian 15-03-2023
Public Assessment Report Public Assessment Report Estonian 03-12-2015
Patient Information leaflet Patient Information leaflet Greek 15-03-2023
Public Assessment Report Public Assessment Report Greek 03-12-2015
Patient Information leaflet Patient Information leaflet English 15-03-2023
Public Assessment Report Public Assessment Report English 03-12-2015
Patient Information leaflet Patient Information leaflet French 15-03-2023
Public Assessment Report Public Assessment Report French 03-12-2015
Patient Information leaflet Patient Information leaflet Italian 15-03-2023
Public Assessment Report Public Assessment Report Italian 03-12-2015
Patient Information leaflet Patient Information leaflet Latvian 15-03-2023
Public Assessment Report Public Assessment Report Latvian 03-12-2015
Patient Information leaflet Patient Information leaflet Lithuanian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-03-2023
Public Assessment Report Public Assessment Report Lithuanian 03-12-2015
Patient Information leaflet Patient Information leaflet Hungarian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 15-03-2023
Public Assessment Report Public Assessment Report Hungarian 03-12-2015
Patient Information leaflet Patient Information leaflet Maltese 15-03-2023
Public Assessment Report Public Assessment Report Maltese 03-12-2015
Patient Information leaflet Patient Information leaflet Dutch 15-03-2023
Public Assessment Report Public Assessment Report Dutch 03-12-2015
Patient Information leaflet Patient Information leaflet Polish 15-03-2023
Public Assessment Report Public Assessment Report Polish 03-12-2015
Patient Information leaflet Patient Information leaflet Portuguese 15-03-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 15-03-2023
Public Assessment Report Public Assessment Report Portuguese 03-12-2015
Patient Information leaflet Patient Information leaflet Romanian 15-03-2023
Public Assessment Report Public Assessment Report Romanian 03-12-2015
Patient Information leaflet Patient Information leaflet Slovak 15-03-2023
Public Assessment Report Public Assessment Report Slovak 03-12-2015
Patient Information leaflet Patient Information leaflet Slovenian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 15-03-2023
Public Assessment Report Public Assessment Report Slovenian 03-12-2015
Patient Information leaflet Patient Information leaflet Finnish 15-03-2023
Public Assessment Report Public Assessment Report Finnish 03-12-2015
Patient Information leaflet Patient Information leaflet Swedish 15-03-2023
Public Assessment Report Public Assessment Report Swedish 03-12-2015
Patient Information leaflet Patient Information leaflet Norwegian 15-03-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 15-03-2023
Patient Information leaflet Patient Information leaflet Icelandic 15-03-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 15-03-2023

Search alerts related to this product

View documents history